GENENTECH PULMOZYME FIRST QUARTER SALES ARE APPROXIMATELY $20 MIL.
Executive Summary
GENENTECH PULMOZYME FIRST QUARTER SALES ARE APPROXIMATELY $20 MIL., Chief Financial Officer Louis Lavigne told the Kidder, Peabody health care conference April 6 in New York City. Pulmozyme (dornase alfa) was launched for the treatment of cystic fibrosis in January. While the company is "pleased" with early sales, "we need a broader picture of usage and of repeat orders both in the U.S. and in Europe before we give expectations for sales for this year," Lavigne said.